Source: Fortune Business Insights
The global anatomic pathology market is on a robust growth trajectory, driven by rising chronic disease prevalence, technological advancements, and expanding healthcare infrastructure worldwide. According to Fortune Business Insights, the market was valued at USD 37.74 billion in 2025 and is projected to grow from USD 40.29 billion in 2026 to USD 74.04 billion by 2034, registering a CAGR of 7.90% during the forecast period.
Anatomic pathology is a medical specialty dedicated to diagnosing diseases through microscopic examination of tissues, organs, and bodily fluids. As chronic conditions such as cancer, inflammatory bowel disease, and autoimmune disorders continue to rise globally, so does the demand for histopathology, immunohistochemistry, and related diagnostic services.
The primary growth driver remains the increasing prevalence of chronic disorders. According to the American Cancer Society (2025), approximately 2.0 million new cancer cases are estimated to occur annually in the U.S. alone. This surge in patient volume directly boosts demand for anatomic pathology products including stainers, tissue processing systems, and microtomes.
The integration of advanced technologies such as artificial intelligence (AI) and digital pathology is also reshaping the market. According to data from the Mayo Clinic (2025), more than 50% of surgical pathology cases are now being digitized and interpreted via digital pathology platforms. This technological shift is improving diagnostic accuracy, enabling remote consultations, and streamlining laboratory workflows.
Additionally, government-backed healthcare infrastructure expansion across Asia Pacific, Latin America, and the Middle East & Africa, along with supportive reimbursement policies for cancer screening, is further accelerating market growth.
Despite strong growth, the market faces notable restraints. The high cost of advanced instruments — including whole-slide imaging (WSI) systems and molecular diagnostic platforms — poses adoption challenges, especially for small and mid-sized laboratories in emerging economies. Stringent regulatory approval processes add to commercialization delays.
Furthermore, limited diagnostic infrastructure in developing countries such as India, Mexico, and South Africa hampers market penetration. As per Springer Nature (2022), the density of pathologists in Africa is fewer than 4 per million population, highlighting the diagnostic gap in low-resource settings.
By type, the products segment dominated with a 63.13% market share in 2026, fueled by increasing test volumes and new regulatory approvals for advanced instruments.
By application, disease diagnosis led with a 71.64% share in 2026, underpinned by growing cancer and autoimmune disease diagnoses worldwide.
By technique, histopathology accounted for 45.62% of the market in 2026, driven by the high volume of tissue slides examined globally — approximately 20 million per year in the U.K. alone, per the Royal College of Pathologists (2025).
By end user, hospitals & ASCs held a dominant 56.54% share in 2026 due to the large and growing patient intake at these facilities.
North America led the global market with a 36.18% share in 2025, valued at USD 13.65 billion, driven by strong healthcare infrastructure, advanced reimbursement policies, and a high volume of diagnostic tests. The U.S. market is estimated to reach USD 12.69 billion in 2026.
Asia Pacific held 29.33% of the global market in 2025, with India and China emerging as key growth contributors. Europe is projected to record a 7.3% growth rate, while Latin America and Middle East & Africa are also gaining momentum through healthcare modernization efforts.
Prominent companies operating in the global anatomic pathology market include:
In June 2024, F. Hoffmann-La Roche Ltd. received U.S. FDA approval for its VENTANA DP 200 whole-slide imaging system. In September 2025, Labcorp partnered with Roche to deploy FDA-cleared slide scanners for chronic disease diagnosis.
Q1. What is the size and share of the global anatomic pathology market? The global anatomic pathology market was valued at USD 37.74 billion in 2025 and is projected to reach USD 74.04 billion by 2034, growing at a CAGR of 7.90% from 2026 to 2034. North America held the largest regional share at 36.18% in 2025, followed by Asia Pacific at 29.33%.
Q2. What are the key factors driving the anatomic pathology market? The market is primarily driven by the rising prevalence of chronic diseases such as cancer and autoimmune disorders, the integration of AI and digital pathology technologies, growing government support for healthcare infrastructure, and an increasing number of oncology-focused clinical trials requiring tissue-based diagnostics.
Q3. Which segment leads the anatomic pathology market by technique? Histopathology is the leading segment by technique, accounting for 45.62% of the market in 2026. Its dominance is attributed to the high global volume of histopathological examinations performed for diagnosing cancer, infectious diseases, and other chronic conditions.
Source: Fortune Business Insights – Anatomic Pathology Market Report